IL1B and type 2 diabetes mellitus: The role of IL-1β in type 2 diabetes was demonstrated by clinical trials using the recombinant IL-1 receptor antagonist anakinra: it improved glycaemic control in individuals with type 2 diabetes [4] and improved inflammation and beta cell function for months after therapy cessation [3].